Advertisement
Advertisement
SABS
SAB Biotherapeutics, Inc. Common Stock
3.07
USDSponsored
-0.03
-0.97%
Nov 10, 15:59 UTC -5
Closed
After-Market
3.07
0.00
0.00%
SAB Biotherapeutics, Inc. Common Stock (SABS) Earnings
SABS Earnings Reports
Positive Surprise Ratio
SABS beat 13 of 21 last estimates.
62%
Next Report
Date of Next Report
Mar 08, 2027
Estimate for Q4 26 (Revenue/ EPS)
--
/-$0.25
Implied change from Q3 26 (Revenue/ EPS)
--
/+4.17%
Implied change from Q4 25 (Revenue/ EPS)
--
/-28.57%
SAB Biotherapeutics, Inc. Common Stock earnings per share and revenue
On Nov 05, 2026, SABS reported earnings of -0.24 USD per share (EPS) for Q3 26, beating the estimate of -0.27 USD, resulting in a 12.85% surprise. Revenue reached --, compared to an expected --, with a 0.00% difference. The market reacted with a -7.55% price change (close before vs. close after earnings).
Looking ahead to Q4 26, -- analysts forecast an EPS of -0.25 USD, with revenue projected to reach -- USD, implying an increase of 4.17% EPS, and increase of 0.00% in Revenue from the last quarter.
Industry Peers’ Earnings
Industry Peers' Earnings displays EPS earnings data from companies in the same industry. Click on a card to view more details.
Kura Oncology, Inc.
Report Date
Nov 10, 2026 For Q3 26
Estimate
-$0.83
Actual
-$0.78
Surprise
+7.00%
Olema Pharmaceuticals, Inc. Common Stock
Report Date
Nov 10, 2026 For Q3 26
Estimate
-$0.63
Actual
-$0.73
Surprise
-14.53%
Autolus Therapeutics plc - ADR
Report Date
Nov 10, 2026 For Q3 26
Estimate
-$0.16
Actual
-$0.21
Surprise
-27.20%
Protalix BioTherapeutics, Inc. Common Stock
Report Date
Nov 10, 2026 For Q3 26
Estimate
-$0.03
Actual
$0.05
Surprise
+265.02%
PepGen Inc. Common Stock
Report Date
Nov 10, 2026 For Q3 26
Estimate
-$0.27
Actual
-$0.28
Surprise
-1.19%
Humacyte, Inc. Common Stock
Report Date
Nov 10, 2026 For Q3 26
Estimate
-$0.09
Actual
-$0.07
Surprise
+22.91%
Seer, Inc. Class A Common Stock
Report Date
Nov 10, 2026 For Q3 26
Estimate
-$0.25
Actual
-$0.25
Surprise
+1.96%
Scholar Rock Holding Corporation Common Stock
Report Date
Nov 10, 2026 For Q3 26
Estimate
-$0.86
Actual
-$0.81
Surprise
+6.18%
TELA Bio, Inc. Common Stock
Report Date
Nov 10, 2026 For Q3 26
Estimate
-$0.16
Actual
-$0.13
Surprise
+20.54%
Atossa Therapeutics, Inc. Common Stock
Report Date
Nov 10, 2026 For Q3 26
Estimate
-$0.90
Actual
-$0.56
Surprise
+38.31%
FAQ
What were SAB Biotherapeutics, Inc. Common Stock's earnings and revenue for the latest quarter Q3 2026?
For Q3 2026, SAB Biotherapeutics, Inc. Common Stock reported EPS of -$0.24, beating estimates by 12.85%, and revenue of $0.00, 0% as expectations.
How did the market react to SAB Biotherapeutics, Inc. Common Stock's Q3 2026 earnings?
The stock price moved down -7.55%, changed from $3.18 before the earnings release to $2.94 the day after.
When is SAB Biotherapeutics, Inc. Common Stock expected to report next?
The next earning report is scheduled for Mar 08, 2027.
What are the forecasts for SAB Biotherapeutics, Inc. Common Stock's next earnings report?
Based on --
analysts, SAB Biotherapeutics, Inc. Common Stock is expected to report EPS of -$0.25 and revenue of -- for Q4 2026.
Which companies are reporting earnings today?
Check FXEmpire's Earnings Calendar for today's list of reporting companies.